Mesenchymal Stem Cells and Tuberculosis: Clinical Challenges and Opportunities

10Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

Abstract

Tuberculosis (TB) is one of the communicable diseases caused by Mycobacterium tuberculosis (Mtb) infection, affecting nearly one-third of the world’s population. However, because the pathogenesis of TB is still not fully understood and the development of anti-TB drug is slow, TB remains a global public health problem. In recent years, with the gradual discovery and confirmation of the immunomodulatory properties of mesenchymal stem cells (MSCs), more and more studies, including our team’s research, have shown that MSCs seem to be closely related to the growth status of Mtb and the occurrence and development of TB, which is expected to bring new hope for the clinical treatment of TB. This article reviews the relationship between MSCs and the occurrence and development of TB and the potential application of MSCs in the treatment of TB.

Cite

CITATION STYLE

APA

Zhang, X., Xie, Q., Ye, Z., Li, Y., Che, Z., Huang, M., & Zeng, J. (2021, July 22). Mesenchymal Stem Cells and Tuberculosis: Clinical Challenges and Opportunities. Frontiers in Immunology. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2021.695278

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free